[{"from": "human", "value": "Describe this molecule. [C][N][C][=C][Branch1][=Branch2][C][=Branch1][Ring2][=N][Ring1][Branch1][O][C][N][C][=C][C][=Branch2][Ring1][O][=N][C][=Branch1][Ring2][=N][Ring1][=Branch1][N][C][C@H1][Branch1][Branch2][C@@H1][Branch1][Ring2][C][Ring1][Branch1][F][N][C][=Branch1][C][=O][C][=C][N][Branch1][=Branch1][C][=N][Ring2][Ring1][Ring1][C]"}, {"from": "gpt", "value": "The molecule is an orally available inhibitor of the epidermal growth factor receptor (EGFR) mutant form T790M, with potential antineoplastic activity. Mavelertinib specifically binds to and inhibits EGFR T790M, a secondary acquired resistance mutation, which prevents EGFR-mediated signaling and leads to cell death in EGFR/T790M-expressing tumor cells. Compared to some other EGFR inhibitors, PF-06747775 may have therapeutic benefits in tumors with T790M-mediated drug resistance. This agent shows minimal activity against wild-type EGFR (WT EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which can inhibit WT EGFR. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization."}]